Skip Navigation


Annals of Oncology Advance Access originally published online on July 12, 2005
Annals of Oncology 2005 16(11):1849-1850; doi:10.1093/annonc/mdi357
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
16/11/1849    most recent
mdi357v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Antonioli, E.
Right arrow Articles by Bosi, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Antonioli, E.
Right arrow Articles by Bosi, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology

Letter to the Editor

Pulmonary hypertension related to thalidomide therapy in refractory multiple myeloma

The first 10% of the full text of this article appears below.

Thalidomide is an effective treatment both in advanced multiple myeloma (MM) and as first-line therapy in combination with dexamethasone or other cytotoxic chemotherapy [1Go, 2Go].

Two cases [3Go, 4Go] of pulmonary hypertension in the absence of thromboembolic events have been described in patients with MM during thalidomide treatment [5Go].

A 63-year-old woman was diagnosed in . . . [Full Text of this Article]

E. Antonioli1, C. Nozzoli1,*, G. Gianfaldoni1, F. Mannelli1, S. Rossi2, S. Betti3, P. Bernardeschi2, G. Fiorentini2 and A. Bosi1

1 Department of Department of Haematology, University of Florence, Azienda Ospedaliera Careggi, Florence; 2 Department of Oncology, General Hospital S.Giuseppe, Empoli, Florence; 3 Department of Medicine, General Hospital S.Giuseppe, Empoli, Florence, Italy

* E-mail: c.nozzoli@dac.unifi.it


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Am Coll CardiolHome page
H. A. Ghofrani, R. J. Barst, R. L. Benza, H. C. Champion, K. A. Fagan, F. Grimminger, M. Humbert, G. Simonneau, D. J. Stewart, C. Ventura, et al.
Future perspectives for the treatment of pulmonary arterial hypertension.
J. Am. Coll. Cardiol., June 30, 2009; 54(1 Suppl): S108 - S117.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C. Lafaras, E. Mandala, E. Verrou, D. Platogiannis, N. Barbetakis, T. Bischiniotis, and K. Zervas
Non-thromboembolic pulmonary hypertension in multiple myeloma, after thalidomide treatment: A pilot study
Ann. Onc., October 1, 2008; 19(10): 1765 - 1769.
[Abstract] [Full Text] [PDF]